{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+equivalent&page=35",
    "query": {
      "intervention": "Placebo equivalent",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 843,
    "total_pages": 85,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+equivalent&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+equivalent&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T06:24:31.206Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00431964",
      "title": "Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "azithromycin 250 mg tablets",
          "type": "DRUG"
        },
        {
          "name": "placebo tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CF Therapeutics Development Network Coordinating Center",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Years to 18 Years"
      },
      "enrollment_count": 263,
      "start_date": "2007-02",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2015-08-19",
      "last_synced_at": "2026-11-17T06:24:31.206Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Hartford, Connecticut • Atlanta, Georgia + 27 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00431964"
    },
    {
      "nct_id": "NCT06265532",
      "title": "Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "EGCG 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for EGCG 300 mg",
          "type": "DRUG"
        },
        {
          "name": "EGCG 600 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for EGCG 600 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hal Chapman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-02-07",
      "completion_date": "2026-01-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-11-17T06:24:31.206Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06265532"
    },
    {
      "nct_id": "NCT00069095",
      "title": "A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Oxaliplatin 130 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine 1000 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab 7.5 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for bevacizumab 7.5 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin 85 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin 200 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil 400 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab 5 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for bevacizumab 5 mg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2035,
      "start_date": "2003-07",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2016-10-06",
      "last_synced_at": "2026-11-17T06:24:31.206Z",
      "location_count": 49,
      "location_summary": "Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Gilroy",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00069095"
    },
    {
      "nct_id": "NCT01687764",
      "title": "Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Generalized Anxiety Disorder",
        "Separation Anxiety Disorder",
        "Social Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Attentional Bias Modification Treatment (ABMT) - Active",
          "type": "OTHER"
        },
        {
          "name": "Attentional Bias Modification Treatment - Placebo",
          "type": "OTHER"
        },
        {
          "name": "Cognitive Behavioral Group Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Psychoeducational Control Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "Hospital de Clinicas de Porto Alegre",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "7 Years to 11 Years"
      },
      "enrollment_count": 90,
      "start_date": "2011-08",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2012-09-19",
      "last_synced_at": "2026-11-17T06:24:31.206Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01687764"
    },
    {
      "nct_id": "NCT01565707",
      "title": "A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder, Overactive"
      ],
      "interventions": [
        {
          "name": "Solifenacin Succinate Suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Urotherapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Astellas Pharma Europe B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 189,
      "start_date": "2012-06-07",
      "completion_date": "2014-01-02",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-11-17T06:24:31.206Z",
      "location_count": 2,
      "location_summary": "Shreveport, Louisiana • Albany, New York",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01565707"
    },
    {
      "nct_id": "NCT04173611",
      "title": "Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "EXPAREL",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-06-08",
      "completion_date": "2020-12-07",
      "has_results": false,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-11-17T06:24:31.206Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04173611"
    },
    {
      "nct_id": "NCT02040298",
      "title": "Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Clemastine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 50,
      "start_date": "2014-01",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-11-17T06:24:31.206Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02040298"
    },
    {
      "nct_id": "NCT04218084",
      "title": "Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Voxelotor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "2 Years to 14 Years"
      },
      "enrollment_count": 236,
      "start_date": "2020-11-11",
      "completion_date": "2024-11-06",
      "has_results": true,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-11-17T06:24:31.206Z",
      "location_count": 13,
      "location_summary": "Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04218084"
    },
    {
      "nct_id": "NCT00611533",
      "title": "Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Menopause",
        "Cognitive Disturbances"
      ],
      "interventions": [
        {
          "name": "atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 60 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2004-05",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2017-04-17",
      "last_synced_at": "2026-11-17T06:24:31.206Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00611533"
    },
    {
      "nct_id": "NCT04249544",
      "title": "Social Decision Making in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Pramipexole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "45 Years to 80 Years"
      },
      "enrollment_count": 18,
      "start_date": "2019-12-03",
      "completion_date": "2022-09-01",
      "has_results": false,
      "last_update_posted_date": "2023-10-18",
      "last_synced_at": "2026-11-17T06:24:31.206Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04249544"
    }
  ]
}